Montefiore Einstein Comprehensive Cancer Center

Running trials

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Source

• Recruiting

  A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT07287150· Phase 2· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Source

• Recruiting

  Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

  NCT06774027· Source

• Recruiting

  A Study of CTD402 in T-ALL/LBL Patients

  NCT07070219· Phase 1/2· Source

• Recruiting

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· Phase 3· Source

• Recruiting

  Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer

  NCT06865339· Phase 2· Source

• Recruiting

  Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

  NCT06745882· Phase 2· Source

• Recruiting

  A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

  NCT06750094· Phase 3· Source

• Recruiting

  TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

  NCT06533826· Phase 2· Source

• Recruiting

  A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

  NCT06662786· Phase 3· Source

• Recruiting

  Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

  NCT06308588· Phase 1/2· Source

• Recruiting

  Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

  NCT06479135· Phase 3· Source

• Recruiting

  Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

  NCT06276491· Phase 1· Source

• Recruiting

  A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

  NCT06196203· Phase 2· Source

• Recruiting

  Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

  NCT05423691· Phase 1· Source

• Active, not recruiting

  Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.

  NCT05457010· Phase 1· Source

• Recruiting

  GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC

  NCT04864054· Phase 1/2· Source

• Active, not recruiting

  A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

  NCT05132582· Phase 3· Source

• Active, not recruiting

  Evolutionary Therapy for Rhabdomyosarcoma

  NCT04388839· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting
• Metastatic breast cancer3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Childhood cancers2 recruiting
• Colorectal cancer2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Prostate cancer2 recruiting
• Endometrial cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Myelodysplastic syndromes1 recruiting
• Ovarian cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

  NCT05451849· Phase 1/2· Source

Trial sites

• Montefiore Einstein Cancer Center1 trial
• Montefiore Einstein Cancer Center5 trials
• Montefiore Einstein Comprehensive Cancer Center12 trials
• Montefiore Einstein Comprehensive Cancer Center (MECCC)1 trial
• Montefiore Medical Cancer Center2 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Myelodysplastic syndromes9 works · 2 trials